# CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION

Mt. Washington Pediatric Hospital, Inc. and Subsidiaries Years Ended June 30, 2024 and 2023 With Report of Independent Auditors

Ernst & Young LLP



# Consolidated Financial Statements and Supplementary Information

Years Ended June 30, 2024 and 2023

## **Contents**

| 1  |
|----|
|    |
| 4  |
| 5  |
| 6  |
| 7  |
|    |
| 41 |
| 43 |
|    |
| 45 |
|    |
| 47 |
|    |



Ernst & Young LLP Suite 310 1201 Wills Street Baltimore, MD 21231 Tel: +1 410 539 7940 Fax: +1 410 783 3832 ev.com

## Report of Independent Auditors

The Board of Trustees Mt. Washington Pediatric Hospital, Inc. and Subsidiaries

## **Opinion**

We have audited the consolidated financial statements of Mt. Washington Pediatric Hospital, Inc. (the Corporation) and subsidiaries, which comprise the consolidated balance sheets as of June 30, 2024 and 2023, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Corporation at June 30, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

## **Basis for Opinion**

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

## Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.



## **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

## In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether
  due to fraud or error, and design and perform audit procedures responsive to those risks.
   Such procedures include examining, on a test basis, evidence regarding the amounts and
  disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit
  procedures that are appropriate in the circumstances, but not for the purpose of expressing
  an opinion on the effectiveness of the Corporation's internal control. Accordingly, no such
  opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.



## **Supplementary Information**

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying supplementary consolidating information is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Ernst + Young LLP

October 25, 2024

## Consolidated Balance Sheets

|   | June 30 |             |    | 0           |
|---|---------|-------------|----|-------------|
|   |         | 2024        |    | 2023        |
| Assets  |         |             |    |             |
| Current assets:   |         |             |    |             |
| Cash and cash equivalents   | \$      | 7,095,944   | \$ | 3,901,062   |
| Current portion of assets limited as to use                                 |         | 177,894     | ·  | 202,670     |
| Patient accounts receivable, net  |         | 7,196,306   |    | 8,883,740   |
| Other accounts receivable   |         | 1,355,664   |    | 1,747,857   |
| Inventories of supplies   |         | 172,988     |    | 152,553     |
| Prepaid expenses and other current assets                                   |         | 467,632     |    | 342,575     |
| Total current assets  |         | 16,466,428  |    | 15,230,457  |
|   |         | ,,,         |    | ,,          |
| Investments   |         | 80,314,832  |    | 74,007,691  |
| A scots limited as to use loss current portion:                             |         |             |    |             |
| Assets limited as to use, less current portion: Eliasberg construction fund |         | 1,249,449   |    | 1,249,449   |
| Funds restricted by donor   |         | 21,189,675  |    | 18,931,858  |
| Self-insurance trust funds  |         | 8,544,763   |    | 7,836,794   |
| Sen-insurance dust funds  |         | 30,983,887  |    | 28,018,101  |
|   |         |             |    |             |
| Property and equipment, net   |         | 33,767,552  |    | 37,622,858  |
| Other assets  |         | 2,760,095   |    | 3,236,422   |
| Total assets  | \$      | 164,292,794 | \$ | 158,115,529 |
| Liabilities and net assets  |         |             |    |             |
| Current liabilities:  |         |             |    |             |
| Current portion of long-term debt   | \$      | 470,000     | \$ | 455,000     |
| Trade accounts payable  | Ψ       | 3,061,563   | Ψ  | 2,894,563   |
| Accrued payroll benefits  |         | 5,178,194   |    | 4,954,744   |
| Advances from third-party payors  |         | 3,327,705   |    | 3,742,843   |
| Current portion of malpractice liabilities                                  |         | 177,894     |    | 202,670     |
| Due to affiliates   |         | 1,376,248   |    | 789,434     |
| Other current liabilities   |         | 1,296,637   |    | 1,714,498   |
| Total current liabilities   |         | 14,888,241  |    | 14,753,752  |
| Malpractice liabilities   |         | 3,983,586   |    | 4,173,042   |
| Long-term debt, less current portion  |         | 1,795,758   |    | 2,259,821   |
| Other long-term liabilities   |         | 984,266     |    | 227,174     |
| Total liabilities   |         | 21,651,851  |    | 21,413,789  |
|   |         | 21,001,001  |    | 21,113,107  |
| Net assets:   |         |             |    |             |
| Without donor restrictions  |         | 119,217,292 |    | 116,039,737 |
| With donor restrictions   |         | 23,423,651  |    | 20,662,003  |
| Total net assets  |         | 142,640,943 |    | 136,701,740 |
| Total liabilities and net assets  | \$      | 164,292,794 | \$ | 158,115,529 |

See accompanying notes to consolidated financial statements.

# Consolidated Statements of Operations and Changes in Net Assets

|   | Year Ended June 30<br>2024 2023 |                         |    | une 30<br>2023 |
|---|---------------------------------|-------------------------|----|----------------|
| On another a recommendation and other accounts                          |                                 | 2024                    |    | 2023           |
| Operating revenue, gains, and other support:                            | \$                              | 65 060 640              | \$ | 62 214 904     |
| Net patient service revenue Other revenue                               | Ф                               | , ,                     | Ф  | 63,214,894     |
|   |                                 | 1,342,821<br>66,412,461 |    | 2,354,984      |
| Total operating revenue, gains, and other support                       |                                 | 00,412,401              |    | 65,569,878     |
| Operating expenses:   |                                 |                         |    |                |
| Salaries, wages, and benefits   |                                 | 48,463,307              |    | 47,031,771     |
| Purchased services and supplies   |                                 | 16,558,388              |    | 16,041,852     |
| Interest expense, net   |                                 | 49,226                  |    | 57,143         |
| Depreciation and amortization   |                                 | 5,726,678               |    | 5,377,463      |
| Total operating expenses  |                                 | 70,797,599              |    | 68,508,229     |
| Operating loss  |                                 | (4,385,138)             |    | (2,938,351)    |
| Nonoperating income and expenses, net:                                  |                                 |                         |    |                |
| Contributions   |                                 | 1,196,156               |    | 1,715,298      |
| Investment income, net  |                                 | 3,827,052               |    | 918,030        |
| Other income and expenses, net  |                                 | (1,210,604)             |    | (1,965,073)    |
| Change in unrealized gains of trading securities                        |                                 | 4,834,265               |    | 4,988,739      |
| Total nonoperating income   |                                 | 8,646,869               |    | 5,656,994      |
| Excess of revenues over expenses  |                                 | 4,261,731               |    | 2,718,643      |
| Net assets released from restrictions used for purchase of property and |                                 |                         |    |                |
| equipment   |                                 | _                       |    | 2,753,749      |
| Change in funded status of defined benefit plan                         |                                 | (1,389,077)             |    | 491,690        |
| Other changes in assets without donor restrictions                      |                                 | 304,901                 |    | 177,819        |
| Increase in net assets without donor restrictions                       |                                 | 3,177,555               |    | 6,141,901      |
| Changes in net assets with donor restriction:                           |                                 |                         |    |                |
| Contributions   |                                 | 1,737,390               |    | 1,074,140      |
| Investment income, net  |                                 | 2,393,728               |    | 786,700        |
| Net unrealized (losses) gains on donor restricted investments           |                                 | (30,525)                |    | 1,131,688      |
| Other changes in assets with donor restrictions                         |                                 | (271,664)               |    | (252,972)      |
| Net assets released from restrictions used for operations               |                                 | (1,067,281)             |    | (733,625)      |
| Net assets released from restrictions used for purchase                 |                                 | (1,007,101)             |    | (700,020)      |
| of property and equipment   |                                 | _                       |    | (2,753,749)    |
| Increase (decrease) in net assets with donor restrictions               |                                 | 2,761,648               |    | (747,818)      |
| Total increase in net assets  Total increase in net assets              |                                 | 5,939,203               |    | 5,394,083      |
| Total mercase in net assets   |                                 | 3,737,403               |    | 5,574,005      |
| Net assets, beginning of year   |                                 | 136,701,740             |    | 131,307,657    |
| Net assets, end of year   | \$                              | 142,640,943             | \$ | 136,701,740    |

See accompanying notes to consolidated financial statements.

## Consolidated Statements of Cash Flows

|   |    | Year Ended June 3 |    |             |
|---|----|-------------------|----|-------------|
|   |    | 2024              |    | 2023        |
| Operating activities  |    |                   | _  |             |
| Increase in net assets  | \$ | 5,939,203         | \$ | 5,394,083   |
| Adjustments to reconcile increase in net assets to net cash provided by (used in) |    |                   |    |             |
| operating activities:   |    |                   |    |             |
| Depreciation and amortization   |    | 5,726,678         |    | 5,377,463   |
| Amortization of debt issue costs  |    | 5,937             |    | 5,937       |
| Net realized (gains) and change in value of trading securities                    |    | (7,448,261)       |    | (5,055,785) |
| Restricted contributions and investment income                                    |    | (2,393,728)       |    | (816,440)   |
| Net unrealized (gains) on investments with donor restrictions                     |    | (30,525)          |    | (1,131,688) |
| Change in funded status of defined benefit plan                                   |    | 1,389,077         |    | (491,690)   |
| Changes in operating assets and liabilities:                                      |    |                   |    |             |
| Net patient accounts receivable   |    | 1,687,434         |    | (2,266,454) |
| Other receivables, prepaid expenses, other current assets, and other assets       |    | 743,463           |    | 614,046     |
| Inventories of supplies   |    | (20,435)          |    | (53,879)    |
| Amounts due to affiliates   |    | 586,814           |    | 568,334     |
| Trade accounts payable, accrued payroll benefits, other current liabilities, and  |    | ,                 |    |             |
| other long-term liabilities   |    | (873,629)         |    | (2,873,733) |
| Advances from third-party payors  |    | (415,138)         |    | (362,933)   |
| Net cash provided by (used in) operating activities                               |    | 4,896,890         |    | (1,092,739) |
| Investing activities  |    |                   |    |             |
| Purchases of property and equipment   |    | (1,871,372)       |    | (6,099,474) |
| Purchases of investments and assets limited to use, net                           |    | (1,584,852)       |    | (170,872)   |
|   |    | (3,456,224)       |    |             |
| Net cash used in investing activities   |    | (3,430,224)       |    | (6,270,346) |
| Financing activities  |    |                   |    |             |
| Repayment of long-term debt   |    | (455,000)         |    | (425,000)   |
| Restricted contributions and investment income                                    |    | 2,393,728         |    | 816,440     |
| Net cash provided by financing activities   |    | 1,938,728         |    | 391,440     |
| Insurance (decrease) in each and each equipple                                    |    | 2 270 204         |    | (6.071.645) |
| Increase (decrease) in cash and cash equivalents                                  |    | 3,379,394         |    | (6,971,645) |
| Cash and cash equivalents at beginning of year, including restricted cash         | _  | 4,085,922         |    | 11,057,567  |
| Cash and cash equivalents at end of year, including restricted cash               | \$ | 7,465,316         | \$ | 4,085,922   |
| Cash and cash equivalents   | \$ | 7,095,944         | \$ | 3,901,062   |
| Restricted cash including assets limited as to use                                | Ψ  | 369,372           | Ψ  | 184,860     |
| Cash and cash equivalents at end of year, including restricted cash               | \$ | 7,465,316         | \$ | 4,085,922   |
| Cash and cash equivalents at end of year, including restricted cash               | Ф  | 1,403,310         | φ  | +,005,922   |
| Supplemental disclosure of cash flow information                                  |    |                   |    |             |
| Cash paid during the year for interest  | \$ | 43,960            | \$ | 51,833      |

See accompanying notes to consolidated financial statements.

## Notes to Consolidated Financial Statements and Schedules

June 30, 2024 and 2023

## 1. Organization

The accompanying consolidated financial statements of Mt. Washington Pediatric Hospital, Inc. and Subsidiaries (the Corporation) include the accounts of Mt. Washington Pediatric Hospital, Inc. (the Hospital) and its wholly owned subsidiaries; Mt. Washington Pediatric Foundation, Inc. (the Foundation); Mt. Washington Pediatric Community Health Services, LLC (Community Health); and Mt. Washington Community Behavioral Health Services, LLC (Behavioral Health). The Corporation is structured as a joint venture with a 50% ownership interest by the University of Maryland Medical System Corporation (UMMS) and a 50% ownership interest by Johns Hopkins Health System Corporation (JHHS).

The Hospital is a not-for-profit, nonstock corporation formed under the laws of the state of Maryland. Its purpose is to operate a pediatric rehabilitation and specialty hospital while providing the highest-quality services and programs to meet the individualized needs of infants, children, and adolescents in a nurturing environment. The Hospital has 102 licensed beds. The Foundation uses its funds and investment income to solely support the Hospital and its programs. Community Health provides off-site rehabilitation and specialty health care services. Behavioral Health provides off-site behavioral health care services.

The Corporation incurred expenses of \$ 751,071 and \$749,700 for the years ended June 30, 2024 and 2023, respectively, for administrative services provided by UMMS. This amount is reflected in purchased services within the Statement of Operations. The Corporation is managed by UMMS, and, accordingly, the results of the Corporation's operations and its financial condition could be different if it were autonomous.

The accompanying consolidated financial statements include the accounts of the Corporation, its wholly owned subsidiaries, and entities controlled by the Corporation. All material intercompany balances and transactions have been eliminated in consolidation.

#### 2. Summary of Significant Accounting Policies

## **Basis of Presentation**

The consolidated financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Cash and Cash Equivalents**

Cash and cash equivalents consist of cash and interest-bearing deposits with maturities of three months or less from date of purchase, excluding amounts presented within investments and assets limited as to use. Cash and cash equivalent balances may exceed amounts insured by federal agencies, and therefore, bear a risk of loss. The Corporation has not experienced such losses on these funds.

## **Inventories of Supplies**

Inventories, consisting primarily of drugs and medical/surgical supplies, are carried at the lower of cost or market, on a first-in, first-out basis.

#### **Investments and Assets Limited as to Use**

The Hospital participates in an investment pool (UMMS investment pool) of one of its owners, UMMS. Each participating member of the investment pool has an undivided interest in the investment pool. The Hospital's percentage interest in the assets of the investment pool was approximately 4.14% and 4.25% at June 30, 2024 and 2023, respectively. Investment income and administrative expenses relating to the investment pool are allocated to the individual members based on this percentage.

The Hospital's investment portfolio, except the self-insurance trust funds and the UMMS investment pool, are classified as trading and are reported in the consolidated balance sheets as long-term assets at June 30, 2024 and 2023. Unrealized holding gains and losses on trading securities with readily determinable market values and investment income, including realized gains and losses, are included in nonoperating income. Investment income is reported net of investment fees.

The Foundation's investment portfolio is classified as trading and is reported in the consolidated balance sheets as long-term assets at June 30, 2024 and 2023. Unrealized holding gains and losses on trading securities, without donor restrictions, with readily determinable market values and investment income, including realized gains and losses, are included in nonoperating income in the accompanying consolidated statements of operations and changes in net assets. Investment income is reported net of investment fees.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

The Hospital measures its investments in the self-insurance trust funds and the UMMS investment pool using the net asset value (NAV) as a practical expedient. Underlying securities of these investments may include certain debt and equity securities that are not readily marketable. Because certain investments are not readily marketable, their fair value is subject to additional uncertainty, and, therefore, values realized upon disposition may vary significantly from current reported values.

Assets limited as to use include investments set aside at the discretion of the board of trustees for the replacement or acquisition of property and equipment over which the board of trustees retains control and may at its discretion use for other purposes, self-insurance trust arrangements, and assets whose use is restricted by donors. Such investments are stated at fair value. Amounts required to meet current liabilities have been included in current assets in the consolidated balance sheets. Changes in fair values of donor-restricted investments are recorded in net assets without donor restriction unless otherwise required by the donor or state law to be included in net assets with donor restriction.

Investments are exposed to certain risks, such as interest rate, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, changes in the value of investment securities could occur in the near term, and these changes could materially differ from amounts reported in the accompanying consolidated financial statements.

## **Fair Value Measurements**

The following methods and assumptions were used by the Corporation in estimating the fair value of its financial instruments:

Cash and cash equivalents, patient and other accounts receivable, assets limited as to use, investments, trade accounts payable, accrued payroll benefits, current and long-term debt, and advances from third-party payors — The carrying amounts reported in the consolidated balance sheets approximate the related fair values.

The Corporation has implemented the provisions of Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, in relation to fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. This guidance

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted market prices (unadjusted) in active markets for identical assets or liabilities that the Corporation has the ability to access at the measurement date.
- Level 2 inputs are inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified contractual term, a Level 2 input must be observable for substantially the full term of the asset or liability.
- Level 3 inputs are unobservable inputs for the asset or liability.

Assets and liabilities classified as Level 1 are valued using unadjusted quoted market prices for identical assets or liabilities in active markets. The Corporation uses techniques consistent with the market approach and the income approach for measuring fair value of its Level 2 and Level 3 assets and liabilities. The market approach is a valuation technique that uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The income approach generally converts future amounts (cash flows or earnings) to a single present value amount (discounted).

The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.

As of June 30, 2024 and 2023, the Level 2 assets utilize the following valuation techniques and inputs:

#### Corporate obligations

The fair value of investments in U.S. and international corporate bonds is primarily determined using techniques that are consistent with the market approach. Significant observable inputs include benchmark yields, reported trades, observable broker/dealer quotes, issuer spreads, and security specific characteristics, such as early redemption options.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

The fair value of collateralized corporate obligations is primarily determined using techniques consistent with the income approach, such as a discounted cash flow model. Significant observable inputs include prepayment speeds and spreads, benchmark yield curves, volatility measures, and quotes.

Self-insurance trust funds and the UMMS investment pool are measured at fair value and represent funds included on the consolidated balance sheet that are reported using NAV as a practical expedient. These amounts are not required to be categorized in the fair value hierarchy. The fair value of these investments is based on the proportionate share of the NAV based on the most recent investment statements. The self-insurance trust funds and the UMMS investment pool are utilizing NAV to calculate fair value and are included in the fair value hierarchy tables presented in Note 3.

#### **Self-Insurance**

Under the Corporation's self-insurance programs (general and professional liability and employee health benefits), incurred claims are estimated primarily based upon actuarial estimates which include both reported and incurred but not reported claims, taking into consideration the severity of incidents and the expected timing of claim payments. These estimates are continually reviewed and adjusted as necessary based on experience. These adjustments are recorded within the current period operating income.

## **Property and Equipment**

Property and equipment are stated at cost or estimated fair value at date of contribution, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the assets are as follows:

| Building and leasehold improvements | 20 to 40 years |
|-------------------------------------|----------------|
| Land improvements                   | 5 to 20 years  |
| Equipment                           | 3 to 15 years  |

Interest cost incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Deferred Financing Costs**

Costs incurred related to the issuance of long-term debt are deferred and are amortized over the life of the related debt using the effective-interest method. Accumulated amortization of such costs amounted to \$ 17,316 and \$11,378 for the years ended June 30, 2024 and 2023, respectively. Deferred financing costs are presented as a component of long-term debt in the accompanying consolidated balance sheets.

## **Advances From Third-Party Payors**

The Hospital receives advances from some of its third-party payors so that those payors can receive the stated prompt pay discount allowed in the State of Maryland. Advances are recorded as a current liability in the consolidated balance sheets.

## **Impairment of Long-Lived Assets**

Management regularly evaluates whether events or changes in circumstances have occurred that could indicate impairment in the value of long-lived assets. In accordance with the provisions of ASC 360, *Property, Plant, and Equipment*, if there is an indication that the carrying amount of an asset is not recoverable, management estimates the projected undiscounted cash flows, excluding interest, to determine if an impairment loss should be recognized. The amount of impairment loss is determined by comparing the historical carrying value of the asset to its estimated fair value. Estimated fair value is determined through an evaluation of recent and projected financial performance using standard industry valuation techniques.

In estimating the future cash flows for determining whether an asset is impaired, the Corporation groups its assets at the lowest level for which there are identifiable cash flows independent of other groups of assets. If such costs are impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. There were no impairments in the years ended June 30, 2024 and 2023.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Net Assets**

The net assets of the Corporation and changes therein are classified as follows:

*Net assets without donor restrictions:* Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Corporation. The Corporation's board may designate assets without restrictions for specific operational purposes from time to time.

*Net assets with donor restrictions:* Net assets subject to stipulations imposed by donors and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Corporation or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity.

#### **Net Patient Service Revenue and Provision for Uncollectible Accounts**

In accordance with ASC 606, *Revenue from Contracts with Customers*, net patient service revenue, which includes hospital inpatient services, hospital outpatient services, and other patient services revenue, is recorded at the transaction price estimated by the Corporation to reflect the total consideration due from patients and third-party payors (including commercial payors and government programs) and others. Revenue is recognized over time as performance obligations are satisfied in exchange for providing goods and services in patient care. Revenue is recorded as these goods and services are provided. The services provided to a patient during an inpatient stay or outpatient visit represent a bundle of goods and services that are distinct and accounted for as a single performance obligation.

The Corporation's estimate of the transaction price includes the Corporation's standard charges for the goods and services provided, with a reduction recorded related to explicit price concessions for such items as contractual allowances, charity care, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. The price concessions are determined using the portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. Based on historical experience, a significant portion of the self-pay population will be unable or unwilling to pay for services which is estimated in the transaction price. Subsequent changes to the estimate of the transaction price are generally recorded as adjustment to net patient service revenue in the period of change. Subsequent changes that are

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

determined to be the result of an adverse change in the payor's or patient's ability to pay are recorded as bad debt expense and recorded within operating expenses in the accompanying consolidated statement of operations and changes in net assets and was not material for the years ended June 30, 2024 and 2023.

Estimates for uncollectible amounts are based on the historical collections experience for similar payors and patients, current market conditions, and other relevant factors. The Corporation recognizes a significant amount of patient service revenue even though they do not assess the patient's ability to pay.

The standard charges for goods and services for the Corporation reflects actual charges to patients based on rates regulated by the state of Maryland Health Services Cost Review Commission (HSCRC) in effect during the period in which the services are rendered. See Note 8 for further discussion on the HSCRC and regulated rates.

Patient accounts receivable consist primarily of amounts owed by various governmental agencies, insurance companies and patients and are recorded at the net realizable value based on certain assumptions determined by each payor. The Corporation reports patient accounts receivable at an amount equal to the consideration it expects to receive in exchange for providing healthcare services to its patients, which is estimated using contractual provisions associated with specific payors, historical reimbursement rates and analysis of past experience to estimate potential adjustments.

The Corporation has elected to apply the optional exemption in ASC 606-10-50-14a, as all performance obligations relate to contracts with duration of less than one year. Under this exemption, the Corporation was not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations, at the end of the year, are completed within days or weeks of the end of the year.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

Operating revenue by line of business are as follows:

|                                   | Year Ended June 30 |                         |    |                         |  |
|-----------------------------------|--------------------|-------------------------|----|-------------------------|--|
|                                   |                    | 2024                    |    | 2023                    |  |
| Hospital<br>Physicians            | \$                 | 62,522,738<br>2,546,902 | \$ | 60,698,717<br>2,516,177 |  |
| Total net patient service revenue |                    | 65,069,640              |    | 63,214,894              |  |
| Other nonpatient care             |                    | 1,342,821               |    | 2,354,984               |  |
| Total operating revenue           | \$                 | 66,412,461              | \$ | 65,569,878              |  |

#### **Charity Care**

The Hospital is committed to providing quality healthcare to all, regardless of one's ability to pay. Patients who meet the criteria of the Hospital's charity care policy receive services without charge or at amounts less than its established rates. The criteria for charity care consider the household income in relation to the federal poverty guidelines. The Hospital provides services at no charge for patients with adjusted gross income equal to or less than 200% of the federal poverty guidelines. For uninsured patients with adjusted gross income greater than 200% of the federal poverty guidelines, a sliding scale discount is applied. Income and asset information is obtained from the patient and subsequent analysis. The Hospital maintains records to identify and monitor the level of charity care it furnished under its charity care policy. The Hospital estimates the total direct and indirect costs to provide charity care were \$107,673 and \$264,092 in the years ended June 30, 2024 and 2023, respectively.

## Nonoperating Income and Expenses, Net

Other activities that are largely unrelated to the Corporation's primary mission are recorded as nonoperating income and expenses, and include investment income, change in fair value of investments and general donations, and fund-raising activities.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Excess of Revenues Over Expenses**

The consolidated statement of operations and changes in net assets includes a performance indicator, the excess of revenues over expenses. Changes in net assets without donor restriction that are excluded from the excess of revenues over expenses, consistent with industry practice, including contributions of long-lived assets (including assets acquired using contributions, which by donor restriction were to be used for the purposes of acquiring such assets), pension-related changes other than net periodic pension costs, and other items, which are required by generally accepted accounting principles to be reported separately.

#### **Income Tax Status**

The Hospital is a not-for-profit corporation as described under Section 501(c)(3) of the Internal Revenue Code (the Code) and is exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. The Foundation is a not-for-profit corporation formed under the laws of the state of Maryland, organized for charitable purposes and recognized by the Internal Revenue Service as a tax-exempt organization under Section 501(c)(3) of the Code.

The Corporation follows a threshold of more likely than not for recognition and derecognition of tax positions taken or expected to be taken in a tax return. Management does not believe that there are any unrecognized tax benefits that should be recognized.

#### **Donor-Restricted Gifts and Pledges Receivable**

Unconditional promises to give cash and other assets to the Corporation are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the promise becomes unconditional. Contributions are reported as either net assets with donor restriction if they are received with donor stipulations that limit the use of the donated assets or net assets without donor restrictions if they are received without donor stipulations. When a donor restriction is satisfied, net assets with donor restriction are reclassified as net assets without donor restriction and either reported in the consolidated statements of operations and changes in net assets as net assets released from restrictions for operations or net assets released from restrictions for property and equipment. Donor-restricted contributions for operations whose restrictions are met within the same year as received are reported as contributions without donor restriction in the accompanying consolidated statement of

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

operations and changes in net assets. Revenue earned from contributed assets is considered unrestricted unless specifically restricted by the donor. Contributions restricted for the acquisition of land, buildings, and equipment are reported as net assets without donor restrictions when assets are placed in service.

Contributions to be received after one year are discounted at an appropriate discount rate commensurate with the risks involved. An allowance for uncollectible contributions receivable is provided based upon management's judgment, including such factors as prior collection history, type of contributions, and nature of fund-raising activity.

Unconditional promises to give cash and other assets are reported at fair value on the date the promise is received. Conditional promises to give, and indications of intentions to give, are reported at fair value on the date the gift is received.

Scheduled payments for pledges receivable for the Corporation are as follows:

|  | Year Ended June 30 |          |  |  |  |
|--|--------------------|----------|--|--|--|
|  | <br>2024           | 2023     |  |  |  |
| Amounts due within 1 year                        | \$<br>927,428 \$   | 686,972  |  |  |  |
| Amounts due in 1–5 years                         | 215,230            | 314,045  |  |  |  |
| Less impact of discounting pledges receivable to |                    |          |  |  |  |
| present value                                    | (11,246)           | (11,082) |  |  |  |
| Total pledges receivable                         | \$<br>1,131,412 \$ | 989,935  |  |  |  |
|  |                    |          |  |  |  |

Management has evaluated these gifts and has determined they are fully collectable.

## **Going Concern**

Management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern within one year after the date the consolidated financial statements are issued. As of the date of this report, there are no conditions or events that raise substantial doubt about the Corporation's ability to continue as a going concern.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 2. Summary of Significant Accounting Policies (continued)

## **Use of Estimates**

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

## **New and Recently Adopted Accounting Standards**

In June 2016, the FASB issued Accounting Standards Update (ASU) 2016-13, Financial Instrument – Credit Losses: Measurement of Credit Losses on Financial Instruments. The previous standard delays the recognition of a credit loss on a financial asset until the loss is probable of occurring. The new standard removes the requirement that a credit loss be probable of occurring for it to be recognized, and requires entities to use historical experience, current conditions, and reasonable and supportable forecasts to estimate their future expected credit losses. The standard is required to be applied using the modified retrospective approach with a cumulative-effect adjustment to net assets, if any, upon adoption. ASU 2016-13 was effective for the Corporation July 1, 2023. There was no significant impact on the Corporation's consolidated financial statements during the year ended June 30, 2024.

#### Reclassifications

Certain reclassifications have been made to the 2023 consolidated financial statements to conform with classifications used in 2024. The reclassifications had no effect on total assets, total liabilities, and changes in net assets previously reported.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 3. Investments and Assets Limited as to Use

The carrying value of assets limited or restricted as to use is summarized as follows:

|  | June 30    |            |    |            |  |  |      |
|--|------------|------------|----|------------|--|--|------|
|  | 2024       |            |    | 2024       |  |  | 2023 |
| Cash and cash equivalents                            | \$         | 369,372    | \$ | 184,860    |  |  |      |
| U.S. government and agency securities                |            | 3,128,554  |    | 2,368,530  |  |  |      |
| Corporate obligations                                |            | 4,962,566  |    | 4,123,702  |  |  |      |
| Common stocks  |            | 13,978,632 |    | 13,504,215 |  |  |      |
| Self-insurance trust funds – MMCIP                   |            | 8,722,657  |    | 8,039,464  |  |  |      |
| Total assets limited or restricted as to use         | ' <u>-</u> | 31,161,781 |    | 28,220,771 |  |  |      |
| Less amounts available for current liabilities       |            | (177,894)  |    | (202,670)  |  |  |      |
| Total assets limited as to use, less current portion | \$         | 30,983,887 | \$ | 28,018,101 |  |  |      |

The Corporation's self-insurance trust funds are held by the Maryland Medicine Comprehensive Insurance Program (MMCIP) for payment of malpractice claims. These assets consist primarily of cash, common stocks, fixed-income securities, corporate obligations, and alternative investments. MMCIP serves as a funding mechanism for the Corporation's malpractice insurance. As MMCIP is not an insurance provider, transactions with MMCIP are recorded under the deposit method of accounting. Accordingly, the Corporation accounts for its participation in MMCIP by carrying limited-use assets representing the amount of funds contributed to MMCIP and recording a liability for claims, which is included in malpractice liabilities in the accompanying consolidated balance sheets.

The composition and carrying value of investments were as follows:

|                                       | June 30 |            |    |            |
|---------------------------------------|---------|------------|----|------------|
|                                       |         | 2024       |    | 2023       |
| Cash and cash equivalents             | \$      | 8,323,480  | \$ | 9,852,984  |
| U.S. government and agency securities |         | 1,171,082  |    | 882,685    |
| Corporate obligations                 |         | 1,857,590  |    | 1,537,243  |
| Common stocks                         |         | 5,232,486  |    | 5,035,179  |
| UMMS investment pool                  |         | 63,730,194 |    | 56,699,600 |
|                                       | \$      | 80,314,832 | \$ | 74,007,691 |

Notes to Consolidated Financial Statements and Schedules (continued)

#### 3. Investments and Assets Limited as to Use (continued)

The Hospital participates in the UMMS investment pool, which invests in a mix of cash and cash equivalents, corporate bonds, U.S. government and agency securities, common stocks, and alternative investments. The alternative investments held within the UMMS investment pool include hedge funds, private equity, and commingled investment funds. As of June 30, 2024 and 2023, the majority of these alternative investments were subject to 30 day or less notice requirements and were available to be redeemed on at least a monthly basis. Each participating member of the UMMS investment pool has an undivided interest in the investment pool. The Hospital values its investments in the UMMS investment pool using NAV as a practical expedient.

Investment income and realized and unrealized gains (losses) for investments limited or restricted as to use and other long-term investments are summarized as follows:

| Year Ended June 30 |               |  |  |  |
|--------------------|---------------|--|--|--|
|                    | 2024          | 2023   |  |  |
| \$                 | 3,606,768 \$  | 1,637,684                                    |  |  |
|                    | 2 614 012     | 67,046                                       |  |  |
|                    | 4,834,265     | 4,988,739                                    |  |  |
|                    | , ,           | , ,  |  |  |
|                    | (30,525)      | 1,131,688                                    |  |  |
| \$                 | 11,024,520 \$ | 7,825,157                                    |  |  |
|                    | ·             | \$ 3,606,768 \$ 2,614,012 4,834,265 (30,525) |  |  |

Total investment return is classified in the consolidated statements of operations and changes in net assets as follows:

| Year Ended June 30 |               |  |  |  |
|--------------------|---------------|--|--|--|
|                    | 2024          | 2023   |  |  |
| \$                 | 3,827,052 \$  | ,  |  |  |
|                    | 2,393,728     | 786,700                                      |  |  |
|                    | (30,525)      | 1,131,688                                    |  |  |
|                    | 4,834,265     | 4,988,739                                    |  |  |
| \$                 | 11,024,520 \$ | 7,825,157                                    |  |  |
|                    |               | \$ 3,827,052 \$ 2,393,728 (30,525) 4,834,265 |  |  |

Notes to Consolidated Financial Statements and Schedules (continued)

## 3. Investments and Assets Limited as to Use (continued)

The following table presents assets that are measured at fair value on a recurring basis, as of June 30, 2024, including the UMMS investment pool measured using NAV, which are not required to be categorized in the fair value hierarchy:

|                                |               |                                       |         | Investments<br>Reported |               |
|--------------------------------|---------------|---------------------------------------|---------|-------------------------|---------------|
|                                | Level 1       | Level 2                               | Level 3 | at NAV                  | Total         |
| Investments:                   |               |                                       |         |                         |               |
| Cash and cash equivalents      | \$ 8,323,480  | \$ -                                  | \$ -    | \$ -                    | \$ 8,323,480  |
| U.S. government and            |               |                                       |         |                         |               |
| agency securities              | 1,171,082     | _                                     | _       | _                       | 1,171,082     |
| Corporate obligations          | _             | 1,857,590                             | _       | _                       | 1,857,590     |
| Common stocks                  | 5,232,486     | _                                     | _       | _                       | 5,232,486     |
| UMMS investment pool           |               |                                       |         | 63,730,194              | 63,730,194    |
| Total investments              | 14,727,048    | 1,857,590                             | _       | 63,730,194              | 80,314,832    |
| Assets limited:                |               |                                       |         |                         |               |
| Cash and cash equivalents      | 369,372       | _                                     | _       | _                       | 369,372       |
| U.S. government and            | 2 22 ,2 1 =   |                                       | _       | _                       |               |
| agency securities              | 3,128,554     | _                                     |         |                         | 3,128,554     |
| Corporate obligations          | _             | 4,962,566                             | _       | _                       | 4,962,566     |
| Common stocks                  | 13,978,632    | , , , , , , , , , , , , , , , , , , , | _       | _                       | 13,978,632    |
| Self-insurance trust           |               |                                       |         |                         |               |
| funds – MMCIP                  | _             | _                                     | _       | 8,722,657               | 8,722,657     |
| Total assets limited as to use | 17,476,558    | 4,962,566                             | _       | 8,722,657               | 31,161,781    |
|                                | \$ 32,203,606 | \$ 6,820,156                          | \$ -    | \$ 72,452,851           | \$111,476,613 |

Notes to Consolidated Financial Statements and Schedules (continued)

## 3. Investments and Assets Limited as to Use (continued)

The following table presents assets that are measured at fair value on a recurring basis, as of June 30, 2023, including the UMMS investment pool measured using NAV, which are not required to be categorized in the fair value hierarchy:

|                                |               |                 |         | Investments<br>Reported |               |
|--------------------------------|---------------|-----------------|---------|-------------------------|---------------|
|                                | Level 1       | Level 2         | Level 3 | at NAV                  | Total         |
| Investments:                   |               |                 |         |                         |               |
| Cash and cash equivalents      | \$ 9,852,984  | \$<br>_         | \$<br>_ | \$ -                    | \$ 9,852,984  |
| U.S. government and            |               |                 |         |                         |               |
| agency securities              | 882,685       | -               | _       | _                       | 882,685       |
| Corporate obligations          | _             | 1,537,243       | _       | _                       | 1,537,243     |
| Common stocks                  | 5,035,179     | _               | _       | _                       | 5,035,179     |
| UMMS investment pool           |               | _               | _       | 56,699,600              | 56,699,600    |
| Total investments              | 15,770,848    | 1,537,243       | _       | 56,699,600              | 74,007,691    |
| Assets limited:                |               |                 |         |                         |               |
| Cash and cash equivalents      | 184,860       | _               | _       | _                       | 184,860       |
| U.S. government and            |               |                 | _       | _                       |               |
| agency securities              | 2,368,530     | -               |         |                         | 2,368,530     |
| Corporate obligations          | _             | 4,123,702       | _       | _                       | 4,123,702     |
| Common stocks                  | 13,504,215    | _               | _       | _                       | 13,504,215    |
| Self-insurance trust           |               |                 |         |                         |               |
| funds – MMCIP                  |               | _               | _       | 8,039,464               | 8,039,464     |
| Total assets limited as to use | 16,057,605    | <br>4,123,702   |         | 8,039,464               | 28,220,771    |
|                                | \$ 31,828,453 | \$<br>5,660,945 | \$<br>_ | \$ 64,739,064           | \$102,228,462 |

Notes to Consolidated Financial Statements and Schedules (continued)

## 4. Property and Equipment

A summary of property and equipment and related accumulated depreciation is as follows:

|                               | June 30 |              |    |              |
|-------------------------------|---------|--------------|----|--------------|
|                               |         | 2024         |    | 2023         |
| Land and land improvements    | \$      | 1,519,755    | \$ | 1,519,854    |
| Buildings and fixed equipment |         | 69,247,735   |    | 68,235,292   |
| Leasehold improvements        |         | 498,384      |    | 500,481      |
| Major moveable equipment      |         | 5,415,508    |    | 5,329,966    |
| Minor equipment               |         | 13,517,213   |    | 12,879,907   |
| Construction-in-process       |         | 294,499      |    | 310,677      |
|                               |         | 90,493,094   |    | 88,776,177   |
| Less accumulated depreciation |         | (56,725,542) |    | (51,153,319) |
| Property and equipment, net   | \$      | 33,767,552   | \$ | 37,622,858   |

Construction in progress includes building and renovation costs for assets that have not yet been placed into service. These costs relate to major construction projects as well as routine renovations under way at the Hospital's facilities.

#### 5. Retirement Plans

The Corporation's defined benefit plan resides within the UMMS Corporate Pension Plan (the Corporate Plan).

Effective for fiscal year 2016, the Corporate Plan was amended to freeze participation for the Corporation employees who were hired after December 31, 2016. Effective for fiscal year 2023, the Corporate Plan was frozen to all participants and the participant's accrued benefit shall not include any credits for accruals or compensation after this date; however, each participant's cash balance account shall continue to earn interest credits effective December 31, 2022.

Notes to Consolidated Financial Statements and Schedules (continued)

## **5. Retirement Plans (continued)**

The following table sets forth the change in the benefit obligation and plan assets as of and for the years ended June 30, the measurement date:

|   |    | 2024          | 2023        |
|---|----|---------------|-------------|
| Change in projected benefit obligations         |    |               |             |
| Benefit obligations at beginning of year:       | \$ | 12,905,976 \$ | 13,921,081  |
| Curtailments                                    |    | _             | (180,512)   |
| Service cost                                    |    | _             | 281,037     |
| Interest cost                                   |    | 694,905       | 692,799     |
| Actuarial loss (gain)                           |    | 1,592,453     | (660,700)   |
| Benefits paid                                   |    | (923,102)     | (1,147,729) |
| Projected benefit obligations at end of year    | \$ | 14,270,232 \$ | 12,905,976  |
|   |    | 2024          | 2023        |
| Change in plan assets                           | -  |               |             |
| Fair value of plan assets at beginning of year: | \$ | 13,536,498 \$ | 13,977,172  |
| Actual return on plan assets                    |    | 604,651       | (188,945)   |
| Employer contributions                          |    | 300,000       | 896,000     |
| Benefits paid                                   |    | (923,102)     | (1,147,729) |
| Fair value of plan assets at end of year        | \$ | 13,518,047 \$ | 13,536,498  |

Notes to Consolidated Financial Statements and Schedules (continued)

## **5. Retirement Plans (continued)**

The funded status of the Corporate Plan and amounts recognized as other assets in the consolidated balance sheets are as follows:

|  | June 30  |                        |          |                    |
|--|----------|------------------------|----------|--------------------|
|  |          | 2024                   |          | 2023               |
| Funded status, end of period:  |          |                        |          |                    |
| Fair value of plan assets  | \$       | 13,518,047             | \$       | 13,536,498         |
| Projected benefit obligations  |          | 14,270,232             |          | 12,905,976         |
| Net funded status  | \$       | (752,185)              | \$       | 630,522            |
| Accumulated benefit obligation at end of year  | \$       | 14,270,232             | \$       | 12,905,976         |
| Amounts recognized in consolidated balance sheets at June 30:  Accrued pension (liability) asset | \$<br>\$ | (752,185)<br>(752,185) | \$<br>\$ | 630,522<br>630,522 |
| Amounts recognized in net assets without donor restriction as of June 30:  Net actuarial loss    | \$       | (3,614,413)            | \$       | (2,228,335)        |
|  | \$       | (3,614,413)            | \$       | (2,228,335)        |

The estimated amounts that will be amortized from net assets with donor restriction into net periodic pension cost in fiscal 2025 are as follows:

| Net actuarial loss | \$<br>314,573 |
|--------------------|---------------|
|                    | \$<br>314,573 |

Notes to Consolidated Financial Statements and Schedules (continued)

#### **5. Retirement Plans (continued)**

The components of net periodic pension cost are as follows:

|                                    | Year Ended June 30 |            |           |  |
|------------------------------------|--------------------|------------|-----------|--|
|                                    |                    | 2024       | 2023      |  |
| Service cost                       | \$                 | - \$       | 281,037   |  |
| Interest cost                      | ·                  | 694,905    | 692,799   |  |
| Expected return on plan assets     |                    | (591,385)  | (574,549) |  |
| Amortization of prior service cost |                    | _          | 195,555   |  |
| Amortization of net actuarial loss |                    | 190,109    | 218,417   |  |
| Total net periodic pension cost    | \$                 | 293,629 \$ | 813,259   |  |

Components of net benefit cost other than the service cost of \$ 0 and \$281,037 were recorded in other nonoperating income and expenses, net in the consolidated statements of operations and changes in net assets for the years ended June 30, 2024 and 2023, respectively. Service cost is included as a component of fringe benefits, which is recorded as salaries, wages, and benefits in the accompanying consolidated statements of operations and changes in net assets.

The assumption information, below, relates to the entire Corporate Plan. Certain information related to the Corporation is not separately identifiable.

The following table presents the weighted average assumptions used to determine benefit obligations for the Corporate Plan:

|                               | June 30    |            |  |
|-------------------------------|------------|------------|--|
|                               | 2024       | 2023       |  |
| Discount rate                 | 5.78%      | 5.67%      |  |
| Rate of compensation increase | N/A        | 3.00       |  |
| Interest crediting rate       | 3.00-5.05% | 3.00-5.00% |  |

Notes to Consolidated Financial Statements and Schedules (continued)

#### **5. Retirement Plans (continued)**

The following table presents the weighted average assumptions used to determine net periodic benefit cost for the Corporate Plan:

|  | Year Ended June 30 |       |  |
|--|--------------------|-------|--|
|  | 2024               | 2023  |  |
| Discount rate                            | 5.67%              | 5.55% |  |
| Expected long-term return on plan assets | 4.50               | 4.15  |  |
| Rate of compensation increase            | N/A                | 3.00  |  |

All of the Corporation Plan's assets are held in the UMMS Master Pension Trust (the Master Trust). The Master Trust invests in a mix of cash and cash equivalents, equity securities, fixed income securities and alternative investments. Alternative investments include hedge funds and commingled investment funds. The majority of these alternative investments held as of June 30, 2024 and 2023, were subject to notice requirements of 30 days or less and were available to be redeemed on at least a monthly basis. Each participating plan has an undivided interest in the Master Trust. The Corporation Plan's percentage interest in the net assets of the Master Trust was approximately 8.61% and 8.69% at June 30, 2024 and 2023, respectively. Investment income and administrative expenses relating to the Master Trust are allocated to the individual plans based on this percentage.

The investment policies of the Corporation's pension plan incorporate asset allocation and investment strategies designed to earn superior returns on plan assets consistent with reasonable and prudent levels of risk. Investments are diversified across classes, sectors, and manager style to minimize the risk of loss. The Corporation uses investment managers specializing in each asset category, and regularly monitors performance and compliance with investment guidelines. In developing the expected long-term rate of return on assets assumption, the Corporation considers the current level of expected returns on risk-free investments, the historical level of the risk premium associated with the other asset classes in which the portfolio is invested, and the expectations for future returns of each asset class. The expected return for each asset class is then weighted based on the target allocation to develop the expected long-term rate of return on assets assumption for the portfolio. The Corporation values its investment in the Master Trust using NAV as a practical expedient.

Notes to Consolidated Financial Statements and Schedules (continued)

## **5. Retirement Plans (continued)**

The Corporate Plan's target allocation and weighted average asset allocations at the measurement date of June 30, by asset category, are as follows:

|                            |            | <b>Percentage of Plan Assets</b> |        |  |  |
|----------------------------|------------|----------------------------------|--------|--|--|
|                            | Target     | June                             | 30     |  |  |
|                            | Allocation | 2024                             | 2023   |  |  |
| Cash and cash equivalents  | 0%-20%     | 14.59%                           | 18.15% |  |  |
| Equity securities          | 15%-25%    | 5.27                             | 4.87   |  |  |
| Fixed-income securities    | 75%-85%    | 80.13                            | 76.93  |  |  |
| Hedge funds/private equity | 0%-20%     | 0.01                             | 0.05   |  |  |
|                            |            | 100%                             | 100%   |  |  |

Funds totaling \$579,120 are subject to notice requirements of 60 days and greater and can be redeemed monthly or quarterly. The Corporation had no unfunded commitments as of June 30, 2024.

The Corporation expects to contribute approximately \$0 to its defined benefit pension plans for the fiscal year ended June 30, 2025.

The following benefit payments, which reflect expected future employee service, as appropriate, are expected to be paid from plan assets in the following years ending June 30:

| 2025      | \$ 1,697,957 |
|-----------|--------------|
| 2026      | 1,207,593    |
| 2027      | 1,138,205    |
| 2028      | 1,184,365    |
| 2029      | 994,419      |
| 2030–2034 | 5,082,707    |

Notes to Consolidated Financial Statements and Schedules (continued)

#### **5. Retirement Plans (continued)**

The expected benefits to be paid are based on the same assumptions used to measure the Corporation's benefit obligation at June 30, 2024.

The Corporation also has a 403(b) retirement plan (Retirement Plan) covering substantially all employees. Employees are immediately eligible for elective deferrals of compensation as contributions to the Retirement Plan. The Retirement Plan currently has a discretionary provision for employer matching contributions. For the years ended June 30, 2024 and 2023, the Corporation made contributions of \$110,983 and \$340,921, respectively.

#### 6. Leases

The Corporation determines if an arrangement is a lease at inception. Operating leases are included in other assets, other current liabilities, and other long-term liabilities on the consolidated balance sheets. The Corporation rents office and clinical space from a related party, and other unrelated third parties. The Corporation has determined these arrangements are leases.

Lease liabilities are recognized based on the present value, net of the future minimum lease payments over the lease term using the Corporation's incremental borrowing rate based on the information available at commencement. The right-of-use (ROU) asset is derived from the lease liability and also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Certain lease agreements for real estate include payments based on actual common area maintenance expenses, and others include rental payments adjusted periodically for inflation. These variable lease payments are recognized in other operating expenses, net, but are not included in the ROU asset or liability balances. Lease agreements may include one or more renewal options which are at the Corporation's sole discretion. The Corporation does not consider the renewal options to be reasonably likely to be exercised therefore, they are not included in ROU assets and lease liabilities. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term for operating leases.

In accordance with ASC 842, the Corporation has elected to not recognize ROU assets and lease liabilities for short-term leases with a lease term of 12 months or less. The Corporation recognizes the lease payments associated with its short-term leases as an expense on a straight-line basis over the lease term. Variable lease payments associated with these leases are recognized and presented in the same manner as all other leases.

Notes to Consolidated Financial Statements and Schedules (continued)

## **6.** Leases (continued)

The following table summarizes the components of operating assets and liabilities classified as current and noncurrent on the accompanying consolidated balance sheets:

|  | <b>Balance Sheet</b>        |    | June 30    |           |  |  |
|--|-----------------------------|----|------------|-----------|--|--|
| Operating Leases                                       | Classification              |    | 2024       | 2023      |  |  |
| Operating lease ROU asset Operating lease obligation – | Other assets                | \$ | 223,340 \$ | 278,889   |  |  |
| current Operating lease obligation –                   | Other current liabilities   |    | (55,094)   | (52,303)  |  |  |
| long term  | Other long-term liabilities |    | (172,080)  | (227,174) |  |  |

The Corporation discounted its leases using a rate of 3.29%. This rate is based on the estimated borrowing rate the Corporation would incur if a loan was obtained to purchase the asset.

For the years ended June 30, 2024 and 2023, the Corporation amortized \$55,549 and \$50,574 in costs related to the ROU asset and incurred interest expense of \$5,099 and \$1,546, respectively. Total rent expense for the lease was \$334,866 and \$311,770 for the years ended June 30, 2024 and 2023, respectively.

Future noncancelable minimum lease payments under operating leases are as follows for the years ending June 30:

| 2025                          | \$<br>59,124  |
|-------------------------------|---------------|
| 2026                          | 60,898        |
| 2027                          | 62,725        |
| 2028                          | 53,572        |
| 2029                          | _             |
| Present value discount        | <br>(9,145)   |
| Total future minimum payments | \$<br>227,174 |
|                               |               |

Notes to Consolidated Financial Statements and Schedules (continued)

## 7. Functional Expenses

The Corporation considers healthcare services and management and general to be its primary functional categories for purposes of expense classification. Accordingly, certain costs have been allocated among healthcare services and management and general. Depreciation is allocated based on square footage. The Corporation's operating expenses by functional classification are as follows:

|  | ]  | Healthcare<br>Services                          | Ianagement nd General                   | Total   |
|--|----|---|---|---|
| Year ended June 30, 2024 Salaries, wages, and benefits Purchased services and supplies Depreciation and amortization Interest expense, net | \$ | 42,208,240<br>11,581,946<br>5,369,906<br>49,226 | \$<br>6,255,067<br>4,976,442<br>356,772 | \$<br>48,463,307<br>16,558,388<br>5,726,678<br>49,226 |
| Total  | \$ | 59,209,318                                      | \$<br>11,588,281                        | \$<br>70,797,599                                      |
| Year ended June 30, 2023 Salaries, wages, and benefits Purchased services and supplies   | \$ | 41,578,494<br>10,197,162                        | \$<br>5,453,277<br>5,844,690            | \$<br>47,031,771<br>16,041,852                        |
| Depreciation and amortization  |    | 5,012,337                                       | 365,126                                 | 5,377,463   |
| Interest expense, net  |    | 57,143  | <br>                                    | <br>57,143  |
| Total  | \$ | 56,845,136                                      | \$<br>11,663,093                        | \$<br>68,508,229                                      |

## 8. Maryland Health Services Cost Review Commission (HSCRC)

Most of the Hospital's revenues are subject to review and approval by the Maryland Health Services Cost Review Commission (HSCRC). Hospital management has filed the required forms with the HSCRC and believes the Hospital to be in compliance with the HSCRC's requirements.

The current rate of reimbursement for services to patients under the Medicare and Medicaid programs is based on an agreement between the Center for Medicare and Medicaid Services (CMS) and the HSCRC. This agreement is based upon a waiver from Medicare reimbursement principles under Section 1814(b) of the Social Security Act and will continue as long as certain conditions are met. Management believes that this program will remain in effect at least through June 30, 2025.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 8. Maryland Health Services Cost Review Commission (HSCRC) (continued)

The Hospital's patient service revenue is recorded at regulated rates regulated by the HSCRC. Such rates are adjusted prospectively, giving effect to, among other things, the projected impact of inflation and variances between actual unit rates and previously approved unit rates (price variances) during the previous year.

The timing of the HSCRC's adjustment for the Hospital could result in an increase or reduction in rates (revenue) due to the variances described above in a year subsequent to the year in which the variances occur. The Hospital's policy is to accrue revenue based on actual charges for services to patients in the year in which the services are performed.

## 9. Long-Term Debt

Long-term debt is comprised of bonds totaling \$3,380,000 issued on August 2, 2021. Interest is payable monthly at a fixed rate of 1.77% through fiscal year 2028.

The annual future maturities of long-term debt according to the original terms of the Loan Agreement are as follows:

| Years ending June 30:                |                 |
|--------------------------------------|-----------------|
| 2026                                 | \$<br>495,000   |
| 2027                                 | 510,000         |
| 2028                                 | 540,000         |
| 2029                                 | 275,000         |
| 2030                                 | _               |
| Total debt                           | <br>1,820,000   |
| Unamortized deferred financing costs | <br>(24,242)    |
|                                      | \$<br>1,795,758 |

The Loan Agreement contains certain restrictive covenants, including requirements that rates and charges be set at certain levels, that incurrence of additional debt be limited and that compliance with certain operating ratios be maintained. As further security under the Loan Agreement, the Foundation has guaranteed the Corporation's repayment of principal and interest due on the bonds.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 10. Insurance

#### **Professional Liability Insurance**

In connection with the affiliation agreement with UMMS and effective July 1, 2006, the Corporation became self-insured with respect to professional and general liability through its participation in the Maryland Medicine Comprehensive Insurance Program Self Insurance Trust (the Trust). The Corporation is self-insured for claims up to the limits of \$1,000,000 on individual claims and \$3,000,000 in the aggregate on an annual basis. For amounts in excess of these limits, the risk of loss has been transferred to the Terrapin Insurance Company (Terrapin), an unconsolidated joint venture of UMMS. Terrapin provides insurance for claims related to UMMS and the Corporation for claims in excess of \$1,000,000 on individual claims and \$3,000,000 in the aggregate up to \$165,000,000 individually and \$227,000,000 in the aggregate under claims made policies between the aforementioned entities and Terrapin. For claims in excess of Terrapin's coverage limits, if any, the Corporation retains the risk of loss.

The Corporation provides for and funds the present value of the costs for professional and general liability claims and insurance coverage related to the projected liability from asserted and unasserted incidents, which the Corporation believes may ultimately result in a loss. These accrued malpractice losses are discounted using a discount rate of 2.5%. In management's opinion, these accruals provide an adequate and appropriate loss reserve. Malpractice liabilities are presented gross of the reinsurance receivable in the accompanying consolidated balance sheets and were \$4,161,480 and \$4,375,712 as of June 30, 2024 and 2023, respectively. Included within the malpractice liabilities are the reinsurance receivables of \$2,382,540 and \$2,349,011 as of June 30, 2024 and 2023, respectively, which have been recorded within other assets.

Total malpractice insurance gain (loss), net of applicable investment returns, for the Corporation in 2024 and 2023 was \$147,625 and (\$375,838), respectively.

## **Workers' Compensation**

The Corporation is insured against workers' compensation claims through membership in the Maryland Hospital Association Workers' Compensation Self-Insurance Group. Premiums are paid quarterly and adjusted yearly based on the group's actual experience.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 10. Insurance (continued)

#### **Health Insurance**

The Corporation maintains a self-insurance plan for employee health insurance. The Corporation has accrued \$388,972 and \$388,972, as of June 30, 2024 and 2023, respectively, for estimated claims incurred but not reported, which are included in accrued payroll benefits.

#### 11. Business and Credit Concentrations

The Corporation provides services to patients in the Baltimore Metropolitan area, the majority of whom are under the age of 18 and are covered by third-party health insurance or state Medicaid programs. Insurance coverage and credit information is obtained from patients upon admission when available. The Corporation bills the insurer directly for services provided. No collateral is obtained for accounts receivable.

The Corporation maintains cash accounts with highly rated financial institutions, which generally exceed federally insured limits. The Corporation has not experienced any losses from maintaining cash accounts in excess of federally insured limits, and, as such, management does not believe the Corporation is subject to any significant credit risks related to this practice.

Net receivables from patients and third-party payors consisted of the following:

|                              | June 30 |      |  |
|------------------------------|---------|------|--|
|                              | 2024    | 2023 |  |
| Medicaid                     | 61%     | 67%  |  |
| Blue Cross                   | 18      | 11   |  |
| Commercial insurance and HMO | 16      | 16   |  |
| Self-pay and others          | 5       | 6    |  |
|                              | 100%    | 100% |  |
|                              |         |      |  |

Notes to Consolidated Financial Statements and Schedules (continued)

#### 11. Business and Credit Concentrations (continued)

Net patient service revenue, by payor class, consisted of the following:

|                              | Jun  | e <b>30</b> |
|------------------------------|------|-------------|
|                              | 2024 | 2023        |
| Medicaid                     | 75%  | 72%         |
| Blue Cross                   | 14   | 13          |
| Commercial insurance and HMO | 10   | 14          |
| Self-pay and others          | 1    | 1           |
|                              | 100% | 100%        |

### 12. Endowment

The Corporation's endowment consists of individual funds established based on donor-imposed restrictions. Net assets associated with endowment funds are classified and reported based on the existence of donor-imposed restrictions.

#### **Interpretation of Relevant Law**

The board of trustees has interpreted UPMIFA as requiring that donor-restricted endowment funds be managed with the long-term objective of at least maintaining the real value (after inflation) of the funds. The Corporation classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the directions of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment funds are classified in restricted net assets until those amounts are appropriated for expenditure by the board of trustees in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the Corporation considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- 1. The duration and preservation of the fund
- 2. The purposes of the Corporation and the donor-restricted endowment fund
- 3. General economic conditions

### Notes to Consolidated Financial Statements and Schedules (continued)

### 12. Endowment (continued)

- 4. The possible effect of inflation and deflation
- 5. The expected total return from income and the appreciation of investments
- 6. The other resources of the Corporation
- 7. The investment policies of the Corporation

Endowment net assets consist of the following:

|                         | Jur              | ie 3 | 0          |
|-------------------------|------------------|------|------------|
|                         | 2024             |      | 2023       |
| Endowment net assets:   |                  |      |            |
| With donor restrictions | \$<br>22,119,751 | \$   | 20,061,447 |

Changes in endowment net assets for the years ended June 30 consist of the following:

|  | With Donor<br>Restriction |
|--|---------------------------|
| Endowment net assets, June 30, 2022:                     | \$ 18,366,291             |
| Investment return, net                                   | 1,918,388                 |
| Contributions  | 29,740                    |
| Amount appropriated for expenditures and other transfers | (252,972)                 |
| Endowment net assets, June 30, 2023:                     | 20,061,447                |
| Investment return, net                                   | 2,363,219                 |
| Contributions  | _                         |
| Amount appropriated for expenditures and other transfers | (304,915)                 |
| Endowment net assets, June 30, 2024                      | \$ 22,119,751             |

Notes to Consolidated Financial Statements and Schedules (continued)

#### 12. Endowment (continued)

#### **Funds With Deficiencies**

From time to time, the fair value of assets associated with an individual donor-restricted endowment fund may fall below the original value of the fund. As of June 30, 2024 and 2023, there are no endowment funds in this position. Subsequent gains that restore the fair value of the assets of the endowment fund to the required level will be classified as an increase in net assets without donor restriction, as appropriate.

### **Return Objectives and Risk Parameters**

The Foundation has adopted investment and funding policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Under the investment policy, as approved by the board of trustees, the endowment assets are invested in a manner that is intended to produce results that exceed the price and yield results of a benchmark that includes the S&P 500, Barclays Government/Credit, and T-Bill Index while assuming a moderate level of investment risk. The Foundation expects its endowment funds, over three to five years, to provide an average annual real rate of return of at least 5%. Actual returns in any given year may vary from this amount.

Notes to Consolidated Financial Statements and Schedules (continued)

### 13. Net Assets – With Donor Restrictions

The Corporation classifies net assets based on the existence or absence of donor-imposed restrictions.

Donor restricted net assets consist of the following:

|  | Jun              | ie 3 | <b>60</b>  |
|--|------------------|------|------------|
|  | 2024             |      | 2023       |
| Subject to expenditure for specific purpose:       |                  |      | _          |
| Funds to be used for programs and capital projects | \$<br>1,303,900  | \$   | 600,556    |
| Callaway Fund                                      | 32,670           |      | 29,180     |
| Endowment funds to be used for renovations         | 4,325,701        |      | 3,863,032  |
| Endowment funds, other                             | <br>16,936,209   |      | 15,344,064 |
| Total  | <br>22,598,480   |      | 19,836,832 |
| Investment in perpetuity:                          |                  |      |            |
| Endowment funds to be used for renovations         | 5,000            |      | 5,000      |
| Endowment funds, other                             | 820,171          |      | 820,171    |
| Total  | <br>825,171      |      | 825,171    |
| Total net assets – with donor restrictions         | \$<br>23,423,651 | \$   | 20,662,003 |

### 14. Liquidity and Availability of Resources

The Corporation has financial assets available to management for general expenditures within one year of the financial reporting date, as follows:

|                                  | Jun              | ie 3 | 0          |
|----------------------------------|------------------|------|------------|
|                                  | <br>2024         |      | 2023       |
| Financial assets:                |                  |      |            |
| Cash and cash equivalents        | \$<br>7,095,944  | \$   | 3,901,062  |
| Patient accounts receivable, net | 7,196,306        |      | 8,883,740  |
| Investments                      | <br>80,314,832   |      | 74,007,691 |
| Total assets                     | \$<br>94,607,082 | \$   | 86,792,493 |

Notes to Consolidated Financial Statements and Schedules (continued)

#### 15. Certain Significant Risks and Uncertainties

The Corporation provides pediatric rehabilitation and specialty services in the state of Maryland. The Corporation and other healthcare providers in Maryland are subject to certain inherent risks, including the following:

- Dependence on revenues derived from reimbursement by the state Medicaid programs;
- Regulation of hospital rates by the State of Maryland Health Services Cost Review Commission;
- Government regulation, government budgetary constraints, and proposed legislative and regulatory changes; and
- Lawsuits alleging malpractice and related claims.

Such inherent risks require the use of certain management estimates in the preparation of the Corporation's consolidated financial statements, and it is reasonably possible that a change in such estimates may occur.

The state Medicaid reimbursement programs represent a substantial portion of the Corporation's revenues and the Corporation's operations are subject to a variety of other federal, state, and local regulatory requirements. Failure to maintain required regulatory approvals and licenses and/or changes in such regulatory requirements could have a significant adverse effect on the Corporation.

Changes in federal and state reimbursement funding mechanisms and related government budgetary constraints could have a significant adverse effect on the Corporation.

The healthcare industry is subject to numerous laws and regulations from federal, state, and local governments. The Corporation's compliance with these laws and regulations can be subject to periodic governmental review and interpretation, which can result in regulatory action unknown or unasserted at this time. Management is aware of certain asserted and unasserted legal claims and regulatory matters arising in the ordinary course of business, none of which, in the opinion of management, is expected to result in losses in excess of insurance limits or have a materially adverse effect on the Corporation's financial position.

Notes to Consolidated Financial Statements and Schedules (continued)

#### 15. Certain Significant Risks and Uncertainties (continued)

The federal government and many states have aggressively increased enforcement under Medicaid anti-fraud and abuse laws and physician self-referral laws (STARK law and regulation). Recent federal initiatives have prompted a national review of federally funded healthcare programs. In addition, the federal government and many states have implemented programs to audit and recover potential overpayments to providers from the Medicaid program. The Corporation has implemented a compliance program to monitor conformance with applicable laws and regulations, but the possibility of future government review and enforcement action exists.

### 16. Subsequent Events

The Corporation evaluated all events and transaction that occurred after June 30, 2024, and through October 25, 2024, the date the consolidated financial statements were issued. The Corporation did not have any material subsequent events during the period.

**Supplementary Information** 

# Consolidating Balance Sheet

June 30, 2024

|   |    | . Washington<br>Pediatric<br>Iospital, Inc. | Pedi   | shington<br>atric<br>tion, Inc. | C  | Washington<br>Pediatric<br>ommunity<br>Health<br>rvices, LLC | C<br>Beha | Washington<br>Pediatric<br>ommunity<br>ivioral Health<br>rvices, LLC | ı  | Elimination<br>Entries | Co | onsolidated<br>Total   |
|---|----|---|--------|---------------------------------|----|--|-----------|--|----|------------------------|----|------------------------|
| Assets  |    |   |        |                                 |    |  |           |  |    |                        |    |                        |
| Current assets:   | ф  | 4.502.555                                   | φ 1    | 146.007                         | ф  | 1 247 200  | ф         |  | ф  |                        | φ  | 7.005.044              |
| Cash and cash equivalents   | \$ | 4,703,557                                   | \$ 1,  | ,146,007                        | \$ | 1,246,380  | Þ         | _  | \$ | _                      | \$ | 7,095,944              |
| Current portion of assets limited as to use Patient accounts receivable |    | 177,894<br>7,052,425                        |        | _                               |    | 133,996  |           | 9,885  |    | _                      |    | 177,894                |
| Other accounts receivable   |    | 1,052,425                                   |        | 448,565                         |    | 343  |           | 1,820  |    | (344,493)              |    | 7,196,306<br>1,355,664 |
| Inventories of supplies   |    | 172,988                                     |        | 440,303                         |    | 343  |           | 1,020  |    | (344,493)              |    | 172,988                |
| Prepaid expenses and other current assets                               |    | 466,806                                     |        | _                               |    | 826  |           | _  |    | _                      |    | 467,632                |
| Total current assets  |    | 13,823,099                                  | 1      | ,594,572                        |    | 1,381,545  |           | 11,705   |    | (344,493)              |    | 16,466,428             |
| Investments   |    | 72,048,838                                  |        | ,265,994                        |    | _  |           |  |    | -                      |    | 80,314,832             |
| Assets limited as to use, less current portion:                         |    |   |        |                                 |    |  |           |  |    |                        |    |                        |
| Eliasberg construction fund   |    | _   | 1.     | 249,449                         |    | _  |           | _  |    | _                      |    | 1,249,449              |
| Funds restricted by donor   |    | 369,372                                     | 20.    | ,820,303                        |    | _  |           | _  |    | _                      |    | 21,189,675             |
| Self-insurance trust funds  |    | 8,544,763                                   |        | _                               |    | _  |           | _  |    | _                      |    | 8,544,763              |
|   |    | 8,914,135                                   | 22,    | ,069,752                        |    | -  |           | -  |    | -                      |    | 30,983,887             |
| Property and equipment, net   |    | 33,767,552                                  |        | _                               |    | _  |           | _  |    | _                      |    | 33,767,552             |
| Economic interest in net assets of the Foundation                       |    | 31,696,243                                  |        | _                               |    | _  |           | _  |    | (31,696,243)           |    | _                      |
| Other assets  |    | 2,760,095                                   |        |                                 |    | <u> </u>   |           | <u> </u>   |    |                        |    | 2,760,095              |
| Total assets  | \$ | 163,009,962                                 | \$ 31, | ,930,318                        | \$ | 1,381,545  | \$        | 11,705   | \$ | (32,040,736)           | \$ | 164,292,794            |

# Consolidating Balance Sheet (continued)

June 30, 2024

|  |     |               |                 | N  | Mt. Washington<br>Pediatric | Mt. Washington<br>Pediatric |    |              |                |
|--|-----|---------------|-----------------|----|-----------------------------|-----------------------------|----|--------------|----------------|
|  | Mt. | Washington    | Mt. Washington  | ì  | Community                   | Community                   |    |              |                |
|  |     | Pediatric     | Pediatric       |    | Health                      | <b>Behavioral Health</b>    | ì  | Elimination  | Consolidated   |
|  | H   | ospital, Inc. | Foundation, Inc |    | Services, LLC               | Services, LLC               |    | Entries      | Total          |
| Liabilities and net assets                 |     |               |                 |    |                             |                             |    |              |                |
| Current liabilities:                       |     |               |                 |    |                             |                             |    |              |                |
| Current portion of long-term debt          | \$  | 470,000       | \$ -            | \$ | _                           | \$ -                        | \$ | _            | \$ 470,000     |
| Trade accounts payable                     |     | 3,056,261     | 234,075         |    | 5,302                       | _                           |    | (234,075)    | 3,061,563      |
| Accrued payroll benefits                   |     | 5,178,194     | _               |    | _                           | _                           |    | _            | 5,178,194      |
| Advances from third-party payors           |     | 3,327,705     | _               |    | _                           | _                           |    | _            | 3,327,705      |
| Current portion of malpractice liabilities |     | 177,894       | _               |    | _                           | _                           |    | _            | 177,894        |
| Due to affiliates                          |     | 1,486,826     | _               |    | (250)                       | 90                          |    | (110,418)    | 1,376,248      |
| Other current liabilities                  |     | 1,295,481     | _               |    | 1,156                       | _                           |    | _            | 1,296,637      |
| Total current liabilities                  |     | 14,992,361    | 234,075         |    | 6,208                       | 90                          |    | (344,493)    | 14,888,241     |
| Malpractice liabilities                    |     | 3,983,586     | -               |    | _                           | _                           |    | _            | 3,983,586      |
| Long-term debt, less current portion       |     | 1,795,758     | _               |    | _                           | _                           |    | _            | 1,795,758      |
| Other long-term liabilities                |     | 984,266       |                 |    |                             |                             |    |              | 984,266        |
| Total liabilities                          |     | 21,755,971    | 234,075         |    | 6,208                       | 90                          |    | (344,493)    | 21,651,851     |
| Net assets:                                |     |               |                 |    |                             |                             |    |              |                |
| Without donor restrictions                 |     | 117,830,340   | 9,576,492       |    | 1,375,337                   | 11,615                      |    | (9,576,492)  | 119,217,292    |
| With donor restrictions                    |     | 23,423,651    | 22,119,751      |    |                             |                             |    | (22,119,751) | 23,423,651     |
| Total net assets                           |     | 141,253,991   | 31,696,243      |    | 1,375,337                   | 11,615                      |    | (31,696,243) | 142,640,943    |
| Total liabilities and net assets           | \$  | 163,009,962   | \$ 31,930,318   | \$ | 1,381,545                   | \$ 11,705                   | \$ | (32,040,736) | \$ 164,292,794 |

See accompanying independent auditors' report.

# Consolidating Balance Sheet

June 30, 2023

|   | Mt. Washington<br>Pediatric<br>Hospital, Inc. | Mt. Washington<br>Pediatric<br>Foundation, Inc. | Mt. Washington Pediatric Community Health Services, LLC | Mt. Washington<br>Pediatric<br>Community<br>Behavioral Health<br>Services, LLC | Elimination<br>Entries | Consolidated<br>Total |
|---|---|---|---|--|------------------------|-----------------------|
| Assets  |   |   |   |  |                        | _                     |
| Current assets:                                   |   |   |   |  |                        |                       |
| Cash and cash equivalents                         | \$ 2,300,196                                  | \$ 1,105,894                                    | \$ 494,972  | \$ -   | \$ - 5                 | 3,901,062             |
| Current portion of assets limited as to use       | 202,670                                       | _   | _   | _  | _                      | 202,670               |
| Patient accounts receivable                       | 8,652,240                                     | _   | 220,061   | 11,439   | _                      | 8,883,740             |
| Other accounts receivable                         | 1,354,108                                     | 772,467   | _   | _  | (378,718)              | 1,747,857             |
| Inventories of supplies                           | 152,553                                       | _   | _   | _  | _                      | 152,553               |
| Prepaid expenses and other current assets         | 340,824                                       | _   | 1,751   | _  | _                      | 342,575               |
| Total current assets                              | 13,002,591                                    | 1,878,361                                       | 716,784   | 11,439   | (378,718)              | 15,230,457            |
| Investments                                       | 66,552,585                                    | 7,455,106                                       | -   | _  | _                      | 74,007,691            |
| Assets limited as to use, less current portion:   |   |   |   |  |                        |                       |
| Eliasberg construction fund                       | _   | 1,249,449                                       | _   | _  | _                      | 1,249,449             |
| Funds restricted by donor                         | 184,860                                       | 18,746,998                                      | _   | _  | _                      | 18,931,858            |
| Self-insurance trust funds                        | 7,836,794                                     | _   | _   | _  | _                      | 7,836,794             |
|   | 8,021,654                                     | 19,996,447                                      | -   | _  | _                      | 28,018,101            |
| Property and equipment, net                       | 37,622,858                                    | _   | _   | _  | _                      | 37,622,858            |
| Economic interest in net assets of the Foundation | 28,951,196                                    | _   | _   | _  | (28,951,196)           | _                     |
| Other assets                                      | 3,236,422                                     | _   | _   | _  | _                      | 3,236,422             |
| Total assets                                      | \$ 157,387,306                                | \$ 29,329,914                                   | \$ 716,784  | \$ 11,439  | \$ (29,329,914) 3      | 5 158,115,529         |

43

# Consolidating Balance Sheet (continued)

June 30, 2023

|  | Washington<br>Pediatric<br>ospital, Inc. | t. Washington<br>Pediatric<br>oundation, Inc. | It. Washington Pediatric Community Health Services, LLC  Mt. Washington Pediatric Community Behavioral Health Services, LLC |    |        |    | Elimination<br>Entries | Co | onsolidated<br>Total |
|--|--|---|---|----|--------|----|------------------------|----|----------------------|
| Liabilities and net assets                 |  |   |   |    |        |    |                        |    |                      |
| Current liabilities:                       |  |   |   |    |        |    |                        |    |                      |
| Current portion of long-term debt          | \$<br>455,000                            | \$<br>_                                       | \$<br>_   | \$ | _      | \$ | _                      | \$ | 455,000              |
| Trade accounts payable                     | 2,894,352                                | 378,718                                       | 211   |    | _      |    | (378,718)              |    | 2,894,563            |
| Accrued payroll benefits                   | 4,954,744                                | _   | _   |    | _      |    | _                      |    | 4,954,744            |
| Advances from third-party payors           | 3,742,843                                | _   | _   |    | _      |    | _                      |    | 3,742,843            |
| Current portion of malpractice liabilities | 202,670                                  | _   | _   |    | _      |    | _                      |    | 202,670              |
| Due to affiliates                          | 789,434                                  | _   | _   |    | _      |    | _                      |    | 789,434              |
| Other current liabilities                  | 1,704,730                                | _   | 9,768   |    | _      |    |                        |    | 1,714,498            |
| Total current liabilities                  | 14,743,773                               | 378,718                                       | 9,979   |    | _      |    | (378,718)              |    | 14,753,752           |
| Malpractice liabilities                    | 4,173,042                                | _   | -   |    | _      |    | _                      |    | 4,173,042            |
| Long-term debt, less current portion       | 2,259,821                                | _   | _   |    | _      |    | _                      |    | 2,259,821            |
| Other long-term liabilities                | <br>227,174                              |   |   |    |        |    |                        |    | 227,174              |
| Total liabilities                          | 21,403,810                               | 378,718                                       | 9,979   |    | _      |    | (378,718)              |    | 21,413,789           |
| Net assets:                                |  |   |   |    |        |    |                        |    |                      |
| Without donor restrictions                 | 115,321,494                              | 8,889,749                                     | 706,805   |    | 11,439 |    | (8,889,750)            |    | 116,039,737          |
| With donor restrictions                    | <br>20,662,002                           | 20,061,447                                    |   |    |        |    | (20,061,446)           |    | 20,662,003           |
| Total net assets                           | 135,983,496                              | 28,951,196                                    | 706,805   |    | 11,439 |    | (28,951,196)           |    | 136,701,740          |
| Total liabilities and net assets           | \$<br>157,387,306                        | \$<br>29,329,914                              | \$<br>716,784   | \$ | 11,439 | \$ | (29,329,914)           | \$ | 158,115,529          |

See accompanying independent auditors' report.

# Consolidating Statement of Operations and Changes in Net Assets

### Year Ended June 30, 2024

|   |      |                           |                             | N  | It. Washington      | . Washington                |             |     |               |   |
|---|------|---------------------------|-----------------------------|----|---------------------|-----------------------------|-------------|-----|---------------|---|
|   | N/I4 | Washington                | Mt Washington               |    | Pediatric           | Pediatric                   |             |     |               |   |
|   | IVI  | . Washington<br>Pediatric | Mt. Washington<br>Pediatric |    | Community<br>Health | Community<br>avioral Health | Elimination |     | Consolidated  |   |
|   | Н    | lospital, Inc.            | Foundation, Inc.            | 9  | Services, LLC       | rvices, LLC                 | Entries     |     | Total         |   |
| Operating revenue, gains, and other support:      |      | <b></b>                   | , , ,                       |    |                     | ,                           |             | _   |               | _ |
| Net patient service revenue                       | \$   | 64,305,659                | \$ -                        | \$ | 432,781             | \$<br>331,200               | \$<br>_     | . ; | \$ 65,069,640 |   |
| Other revenue                                     |      | 1,291,020                 | _                           |    | 9,801               | 42,000                      | _           |     | 1,342,821     |   |
| Total operating revenue, gains, and other support |      | 65,596,679                | _                           |    | 442,582             | 373,200                     | _           |     | 66,412,461    | _ |
| Operating expenses:                               |      |                           |                             |    |                     |                             |             |     |               |   |
| Salaries, wages, and benefits                     |      | 47,817,622                | _                           |    | 531,207             | 114,478                     | _           |     | 48,463,307    |   |
| Purchased services and supplies                   |      | 16,457,701                | _                           |    | 94,567              | 6,120                       | _           |     | 16,558,388    |   |
| Interest expense, net                             |      | 49,226                    | _                           |    | _                   | _                           | _           |     | 49,226        |   |
| Depreciation and amortization                     |      | 5,726,678                 | _                           |    | _                   | _                           | _           |     | 5,726,678     |   |
| Total operating expenses                          |      | 70,051,227                | _                           |    | 625,774             | 120,598                     | _           |     | 70,797,599    |   |
| Operating (loss) income                           |      | (4,454,548)               | _                           |    | (183,192)           | 252,602                     | _           |     | (4,385,138)   | ) |
| Nonoperating income and expenses, net:            |      |                           |                             |    |                     |                             |             |     |               |   |
| Contributions                                     |      | 927,610                   | 268,546                     |    | _                   | _                           | _           |     | 1,196,156     |   |
| Investment income, net                            |      | 2,793,851                 | 1,033,201                   |    | _                   | _                           | _           |     | 3,827,052     |   |
| Other income and expenses, net                    |      | (293,267)                 | (917,301)                   |    | (36)                | _                           | _           |     | (1,210,604)   | ) |
| Change in unrealized gains of trading securities  |      | 4,835,494                 | (1,229)                     |    |                     |                             |             |     | 4,834,265     | _ |
| Total nonoperating income                         |      | 8,263,688                 | 383,217                     |    | (36)                |                             |             |     | 8,646,869     |   |
| Excess (deficit) of revenues over expenses        |      | 3,809,140                 | 383,217                     |    | (183,228)           | <br>252,602                 |             |     | 4,261,731     | _ |

## Consolidating Statement of Operations and Changes in Net Assets (continued)

Year Ended June 30, 2024

|  | . Washington<br>Pediatric<br>Iospital, Inc. | Washington<br>Pediatric<br>ndation, Inc. | At. Washington Pediatric Community Health Services, LLC | Mt. Washin<br>Pediatri<br>Communi<br>Behavioral H<br>Services, L | c<br>ity<br>Iealth | l  | Elimination<br>Entries | (  | Consolidated<br>Total |
|--|---|--|---|--|--------------------|----|------------------------|----|-----------------------|
| Excess (deficit) of revenues over expenses (from previous page)                              | \$<br>3,809,140                             | \$<br>383,217                            | \$<br>(183,228)   | \$ 252   | ,602               | \$ | -                      | \$ | 4,261,731             |
| Change in economic interest in the Foundation Net assets released from restrictions used for | 686,742                                     | -  | -   |  | -                  |    | (686,742)              |    | -                     |
| purchase of property and equipment Transfers in and out                                      | (597,958)                                   | (1,375)                                  | 851,760   | (252   | ,427)              |    | _                      |    | _                     |
| Change in funded status of defined benefit plan  | (1,389,077)                                 | (1,373)                                  | 031,700   | (232   | ,=21)              |    | _                      |    | (1,389,077)           |
| Other changes in assets without donor restrictions   | (1,00),077)                                 | 304,900                                  | _   |  | 1                  |    | _                      |    | 304,901               |
| Increase (decrease) in net assets without donor restrictions                                 | 2,508,847                                   | 686,742                                  | 668,532   |  | 176                |    | (686,742)              |    | 3,177,555             |
| Changes in net assets with donor restriction:  |   |  |   |  |                    |    |                        |    |                       |
| Contributions  | 1,737,390                                   | _  | _   |  | _                  |    | _                      |    | 1,737,390             |
| Investment income, net   |   | 2,393,728                                | _   |  | _                  |    | _                      |    | 2,393,728             |
| Net unrealized gains on donor restricted investments   | _   | (30,525)                                 | _   |  | _                  |    | _                      |    | (30,525)              |
| Change in economic interest in the Foundation  | 2,058,305                                   | _  | -   |  | _                  |    | (2,058,305)            |    | _                     |
| Other changes in assets with donor restrictions  | 33,234                                      | (304,898)                                | _   |  | -                  |    | _                      |    | (271,664)             |
| Net assets released from restrictions used for operations                                    | (1,067,281)                                 | _  | _   |  | _                  |    | _                      |    | (1,067,281)           |
| Net assets released from restrictions used for purchase                                      |   |  |   |  |                    |    |                        |    |                       |
| of property and equipment  | <br>-                                       | -  | _   |  |                    |    | (2.050.205)            |    | -                     |
| Increase (decrease) in net assets with donor restrictions                                    | 2,761,648                                   | 2,058,305                                | -   |  |                    |    | (2,058,305)            |    | 2,761,648             |
| Total increase (decrease) in net assets  | 5,270,495                                   | 2,745,047                                | 668,532   |  | 176                |    | (2,745,047)            |    | 5,939,203             |
| Net assets, beginning of year  | 135,983,496                                 | 28,951,196                               | 706,805   | 11   | ,439               |    | (28,951,196)           |    | 136,701,740           |
| Net assets, end of year  | \$<br>141,253,991                           | \$<br>31,696,243                         | \$<br>1,375,337   | \$ 11  | ,615               | \$ | (31,696,243)           | \$ | 142,640,943           |

See accompanying independent auditors' report.

# Consolidating Statement of Operations and Changes in Net Assets

### Year Ended June 30, 2023

|   | t. Washington<br>Pediatric<br>Hospital, Inc. | Pec | ashington<br>liatric<br>ation, Inc. | It. Washington Pediatric Community Health Services, LLC | Beh | t. Washington Pediatric Community navioral Health ervices, LLC | Elimination<br>Entries |     | Consolidated<br>Total |
|---|--|-----|-------------------------------------|---|-----|--|------------------------|-----|-----------------------|
| Operating revenue, gains, and other support:      |  |     |                                     |   |     |  |                        |     |                       |
| Net patient service revenue                       | \$<br>62,484,804                             | \$  | _                                   | \$<br>486,190   | \$  | 243,900  | \$<br>_                | - 1 | \$ 63,214,894         |
| Other revenue                                     | <br>2,308,253                                |     | _                                   | 4,731   |     | 42,000   |                        | -   | 2,354,984             |
| Total operating revenue, gains, and other support | 64,793,057                                   |     | _                                   | 490,921   |     | 285,900  | _                      | -   | 65,569,878            |
| Operating expenses:                               |  |     |                                     |   |     |  |                        |     |                       |
| Salaries, wages, and benefits                     | 46,478,411                                   |     | _                                   | 436,171   |     | 117,189  | _                      | -   | 47,031,771            |
| Purchased services and supplies                   | 15,941,238                                   |     | _                                   | 94,614  |     | 6,000  | _                      | -   | 16,041,852            |
| Interest expense, net                             | 57,143                                       |     | _                                   | _   |     | _  | _                      | -   | 57,143                |
| Depreciation and amortization                     | 5,377,463                                    |     | _                                   | _   |     | _  | _                      | -   | 5,377,463             |
| Total operating expenses                          | <br>67,854,255                               |     | _                                   | 530,785   |     | 123,189  | _                      | -   | 68,508,229            |
| Operating (loss) income                           | (3,061,198)                                  |     | _                                   | (39,864)  |     | 162,711  | =                      |     | (2,938,351)           |
| Nonoperating income and expenses, net:            |  |     |                                     |   |     |  |                        |     |                       |
| Contributions                                     | 652,790                                      |     | 1,062,508                           | _   |     | _  | _                      | -   | 1,715,298             |
| Investment income, net                            | 581,838                                      |     | 336,192                             | _   |     | _  | _                      | -   | 918,030               |
| Other income and expenses, net                    | (548,673)                                    | (   | 1,416,400)                          | _   |     | _  | _                      | -   | (1,965,073)           |
| Change in unrealized gains of trading securities  | <br>4,512,458                                |     | 476,281                             | _   |     | _  | _                      | -   | 4,988,739             |
| Total nonoperating income                         | 5,198,413                                    |     | 458,581                             |   |     | _  | _                      | -   | 5,656,994             |
| Excess (deficit) of revenues over expenses        | <br>2,137,215                                |     | 458,581                             | <br>(39,864)  |     | 162,711  | <br>_                  |     | 2,718,643             |

## Consolidating Statement of Operations and Changes in Net Assets (continued)

Year Ended June 30, 2023

|  |    | Mt. Washington<br>Pediatric<br>Hospital, Inc. |    | Mt. Washington<br>Pediatric<br>Foundation, Inc. |    | Mt. Washington Pediatric Community Health Services, LLC |    | Mt. Washington Pediatric Community Behavioral Health Services, LLC |    | Elimination<br>Entries |    | Consolidated<br>Total |  |
|--|----|---|----|---|----|---|----|--|----|------------------------|----|-----------------------|--|
| Excess (deficit) of revenues over expenses (from previous page)                              | \$ | 2,137,215                                     | \$ | 458,581   | \$ | (39,864)  | \$ | 162,711  | \$ | _                      | \$ | 2,718,643             |  |
| Change in economic interest in the Foundation Net assets released from restrictions used for |    | 711,553                                       |    | _   |    | _   |    | _  |    | (711,553)              |    | _                     |  |
| purchase of property and equipment   |    | 2,753,749                                     |    | _   |    | <u>-</u>  |    | _  |    | _                      |    | 2,753,749             |  |
| Transfers in and out   |    | 1,225,739                                     |    | _   |    | (1,066,411)   |    | (159,328)  |    | _                      |    | <del>-</del>          |  |
| Change in funded status of defined benefit plan  |    | 491,690                                       |    | _   |    | _   |    | _  |    | _                      |    | 491,690               |  |
| Other changes in assets without donor restrictions   |    | (75,153)                                      |    | 252,972   |    | _   |    | _  |    | _                      |    | 177,819               |  |
| Increase (decrease) in net assets without donor restrictions                                 |    | 7,244,793                                     |    | 711,553   |    | (1,106,275)   |    | 3,383  |    | (711,553)              |    | 6,141,901             |  |
| Changes in net assets with donor restriction:  |    |   |    |   |    |   |    |  |    |                        |    |                       |  |
| Contributions  |    | 1,044,400                                     |    | 29,740  |    | _   |    | _  |    | _                      |    | 1,074,140             |  |
| Investment income, net   |    | , , , <u> </u>                                |    | 786,700   |    | _   |    | _  |    | _                      |    | 786,700               |  |
| Net unrealized gains on donor restricted investments   |    | _   |    | 1,131,688                                       |    | _   |    | _  |    | _                      |    | 1,131,688             |  |
| Change in economic interest in the Foundation  |    | 1,695,156                                     |    |   |    | _   |    | _  |    | (1,695,156)            |    |                       |  |
| Other changes in assets with donor restrictions  |    | _   |    | (252,972)                                       |    | _   |    | _  |    | _                      |    | (252,972)             |  |
| Net assets released from restrictions used for operations                                    | 3  | (733,625)                                     |    | _   |    | _   |    | _  |    | _                      |    | (733,625)             |  |
| Net assets released from restrictions used for purchase                                      |    |   |    |   |    |   |    |  |    |                        |    |                       |  |
| of property and equipment  |    | (2,753,749)                                   |    | _   |    | _   |    | _  |    | _                      |    | (2,753,749)           |  |
| (Decrease) increase in net assets with donor restrictions                                    |    | (747,818)                                     |    | 1,695,156                                       |    | _   |    | _  |    | (1,695,156)            |    | (747,818)             |  |
| Total increase (decrease) in net assets  |    | 6,496,975                                     |    | 2,406,709                                       |    | (1,106,275)   |    | 3,383  |    | (2,406,709)            |    | 5,394,083             |  |
| Net assets, beginning of year  |    | 129,486,521                                   |    | 26,544,487                                      |    | 1,813,080   |    | 8,056  |    | (26,544,487)           |    | 131,307,657           |  |
| Net assets, end of year  | \$ | 135,983,496                                   | \$ | 28,951,196                                      | \$ | 706,805   | \$ |  | \$ | (28,951,196)           | \$ | 136,701,740           |  |

See accompanying independent auditors' report.

### **EY** | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2024 Ernst & Young LLP. All Rights Reserved.

ey.com